Add Formweb to your mobile device
Search results for:
blinatumomab
blinatumomab
Brand names: Blincyto
| Form | Strength | ANAN | ASMP | LACH | LALK | LOHH | LOLR | LOWC | SDSD | SESE | SFSF | Formulary Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SOLUTION, INTRAVENOUS | 35 mcg | "Restricted to FDA approved indications of Acute Lymphoblastic Leukemia (B-cell precursor) *Blincyto must be started before 10am*" |
Last updated: Jul. 10, 2024
- Black Box Warning: Cytokine Release Syndrome and Neurological Toxicities
- Restricted: Blinatumomab (Blincyto) is formulary restricted to FDA approved indications of Acute Lymphoblastic Leukemia (B-cell precursor)
Blincyto must be started before 10am